Health
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and prese
About this update from Beyond Air, Inc.
[{"type":"image","alt":"Beyond Air™","displaySize":"","headline":null,"caption":"Beyond Air™","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/283e6374c7eeb2f53ca652917eb5334d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cVMIN3hdiWRLf4negBQkjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/283e6374c7eeb2f53ca652917eb5334d","width":264,"height":50}},"lazy":false},{"type":"text","content":"GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and presenting mounting evidence that high‑dose iNO may function as a novel broad‑spectrum antimicrobial therapy for a wide range of respiratory infections. Titled “The therapeutic potential of high‑dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions,” the article was published in Intensive Care Medicine Experimental (ICMx), a peer-reviewed, open-access journal of the European Society of Intensive Care Medicine, published by Springer Nature Switzerland AG.","length":993,"tagName":"p"},{"type":"text","content":"The article reviews the emerging clinical evidence supporting the safe administration of iNO at concentrations far exceeding the traditional doses currently used for vasodilation. Its authors synthesized clinical and mechanistic data from 27 studies conducted in both in-hospital and at-home settings– including early‑phase clinical trials in pneumonia, COVID‑19, bronchiolitis, and nontuberculous mycobacteria (NTM) – to illustrate the breadth of ongoing research. The paper highlights the unique multimodal activity of high‑dose iNO, including direct microbial killing, biofilm disruption, antiviral effects, inflammation reduction, and enhanced mucociliary clearance. It also outlines a potential roadmap for future research, emphasizing opportunities in hospital‑acquired pneumonia, ventilator‑as...